Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Not infrequently, a physician is faced with uncertainty regarding the ability of a patient to
perform adequate exercise in the noninvasive evaluation of known or suspected coronary artery
disease (CAD) by the use of radionuclide stress myocardial perfusion imaging. In selected
patients, protocols that combine exercise (either low-level or symptom-limited) with
vasodilator stress agents have been found to be safe and effective in both identification of
the presence and severity of CAD as well as risk stratification for adverse cardiac outcome.
However, currently utilized combined stress protocols have drawbacks. Further refinement of
combined stress protocols would potentially lead to more appropriate stress protocol
selection for patients while enhancing laboratory efficiency. The purpose of this
prospective, randomized study will be to evaluate the relative merits of combining
regadenoson with symptom-limited exercise in patients clinically-referred for
vasodilator-exercise stress myocardial perfusion imaging for the assessment of known or
suspected CAD. It is hypothesized that combining regadenoson with symptom-limited exercise is
a safe and feasible stress testing modality which is non-inferior to that which combines
symptom-limited exercise with dipyridamole.